{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0278","upperLimit":"0.0917","value":"0.0340"}]}],"title":"ADC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0243","upperLimit":"1.89","value":"0.0340"}]}],"title":"TAb"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"2.93","value":"2.00"}]}],"title":"MMAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Tmax was derived from the PK blood samples collected.","dispersionType":"Full Range","groups":[{"description":"Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.","id":"OG000","title":"Enfortumab Vedotin 1.25 mg/kg"}],"paramType":"MEDIAN","populationDescription":"PKAS population.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-dose, EOI, 2 hour, 4 hour post-dose (each cycle = 28 days)","title":"PK of ADC, TAb, MMAE in Serum: Time to Maximum Concentration (Tmax) at Cycle 1 Day 1","type":"PRIMARY","unitOfMeasure":"days"}